The global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward ...

Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on ...

Pfizer PFE reported second-quarter 2025 adjusted earnings per share of 78 cents, which comprehensively beat the Zacks Consensus Estimate of 58 cents per share. Earnings rose 30% year over year.

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...

Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to reduce expenses should help it navigate tariff-related challenges. Some ...

Pfizer PFE and AbbVie ABBV are both U.S. pharmaceutical giants with a strong leadership position in various therapeutic areas. For Pfizer, oncology sales comprise around 28% of its total revenues.

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (OLMA) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going ...